Genetic polymorphisms of <i>transient receptor potential melastatin 1</i> correlate with voriconazole‐related visual adverse events

Jiang, Ying-Kui; Wang, Ruiying; Wang, Xuan; Zhao, Hua-Zhen; Zhou, Linghong; Huang, Liping; Yip, Ching-Wan; Cheng, Jia-Hui; Que, Chun-Xing; Chen, Jiang; Zhu, Liping

doi:10.1111/myc.13080

Cited by 3 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, the visual disturbances associated with voriconazole are likely due to block of transient receptor potential melastatin 1 (TRPM1) channels in retinal ON-bipolar cells [44]. Jiang et al [45] reported the TRPM1 genetic polymorphisms correlated with voriconazole-related visual adverse events. All those situations might influence the relationship between CYP2C19 polymorphisms and neurotoxicity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysis

Zhang

Hou

et al. 2022

Pharmacogenetics and Genomics

View full text Add to dashboard Cite

Objective To assess the impact of cytochrome P450 (CYP) 2C19 polymorphisms on the clinical efficacy and safety of voriconazole. Methods We systematically searched PubMed, EMBASE, CENTRAL, ClinicalTrials.gov, and three Chinese databases from their inception to 18 March 2021 using a predefined search algorithm to identify relevant studies. Studies that reported voriconazole-treated patients and information on CYP2C19 polymorphisms were included. The efficacy outcome was success rate. The safety outcomes included overall adverse events, hepatotoxicity, and neurotoxicity. Results A total of 20 studies were included. Intermediate metabolizers (IMs) and poor metabolizers (PMs) were associated with increased success rates compared with normal metabolizers (NMs) [risk ratio (RR), 1.18; 95% confidence interval (CI), 1.03–1.34; I2 = 0%; P = 0.02; RR, 1.28; 95% CI, 1.06–1.54; I2 = 0%; P = 0.01]. PMs were at increased risk of overall adverse events in comparison with NMs and IMs (RR, 2.18; 95% CI, 1.35–3.53; I2 = 0%; P = 0.001; RR, 1.80; 95% CI, 1.23–2.64; I2 = 0%; P = 0.003). PMs demonstrated a trend towards an increased incidence of hepatotoxicity when compared with NMs (RR, 1.60; 95% CI, 0.94–2.74; I2 = 27%; P = 0.08), although there was no statistically significant difference. In addition, there was no significant association between CYP2C19 polymorphisms and neurotoxicity. Conclusion IMs and PMs were at a significant higher success rate in comparison with NMs. PMs were significantly associated with an increased incidence of all adverse events compared with NMs and IMs. Researches are expected to further confirm these findings. Additionally, the relationship between hepatotoxicity and CYP2C19 polymorphisms deserves clinical attention.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Jiang et al . [45] reported the TRPM1 genetic polymorphisms correlated with voriconazole-related visual adverse events. All those situations might influence the relationship between CYP2C19 polymorphisms and neurotoxicity.…”

Section: Discussionmentioning

confidence: 99%

Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysis

Zhang

Hou

et al. 2022

Pharmacogenetics and Genomics

View full text Add to dashboard Cite

show abstract

Voriconazole

2020

Reactions Weekly

View full text Add to dashboard Cite

Clinical characteristics of drug-induced optic neuropathy cases associated with voriconazole administration for chronic pulmonary aspergillosis

Sato,

Suzuki,

Nakayama

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Visual abnormalities are relatively common side effects of voriconazole use, but optic neuropathy is rare and not well recognized. The aim of this study was to investigate the characteristics of patients diagnosed with optic neuropathy during voriconazole treatment. Methods We reviewed six patients who developed optic neuropathy during voriconazole treatment at our hospital. Visual acuity and critical flicker fusion frequency (CFF) tests were used to diagnose optic neuropathy. Results Voriconazole was used to treat chronic pulmonary aspergillosis in all patients. The median time to onset of optic neuropathy was 181 (72–292) days, the dose was 5.87 (5.55–10.36) mg/kg/day, and the trough value was 1.85 (0.59–2.37) µg/ml. One patient was not using any other drugs during voriconazole treatment, but the other five patients used ethambutol concomitantly. The median dose of ethambutol was 13.89 (12.93–15.63) mg/kg/day, which was within the optimal range, and the duration of use was 70 (22–104) months. The participants using ethambutol had been using the drug for a longer period than typically associated with ethambutol-induced optic neuropathy. Peripheral neuropathy of the lower extremities was observed in four of six cases, coinciding with the appearance of optic neuropathy. Conclusions Voriconazole-associated optic neuropathy may be more likely to occur in cases of concomitant ethambutol treatment or peripheral neuropathy. It is important to be aware of possible optic neuropathy during voriconazole treatment and to perform visual acuity examinations for early detection.

show abstract

Genetic polymorphisms of transient receptor potential melastatin 1 correlate with voriconazole‐related visual adverse events

Cited by 3 publications

References 38 publications

Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysis

Impact of cytochrome P450 2C19 polymorphisms on the clinical efficacy and safety of voriconazole: an update systematic review and meta-analysis

Voriconazole

Clinical characteristics of drug-induced optic neuropathy cases associated with voriconazole administration for chronic pulmonary aspergillosis

Contact Info

Product

Resources

About